Global Haemophilia Market, By Treatment (Medication, Desmopressin, Emicizumab, Anti-fibrinolytics, Factor Replacement Therapy, Desmopressin and Fibrin Sealants, Monoclonal Antibodies, ITI Therapy, Gene Therapy, Fibrin Sealants, and Others), Route of Administration (Oral, Injectable, and Others), Diagnosis (Blood Test, Genetic Tests, and Others), Patient (Pediatric, and Adult), Type (Haemophilia A, Haemophilia B, Haemophilia C, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031.
Haemophilia Market Analysis and Size
Gene therapy in the context of the haemophilia involves using genetic engineering techniques to introduce functional copies of the deficient clotting factor genes (Factor VIII for Hemophilia A or Factor IX for Hemophilia B) into patients cells. This approach aims to enable the production of clotting factors within the body, potentially providing a long-term or even permanent solution to haemophilia treatments. Recent advancements have shown promising results, with ongoing clinical trials demonstrating the feasibility and efficacy of gene therapy in reducing bleeding episodes and lessening dependence on regular clotting factor replacement therapies.
The global haemophilia market size was valued at USD 12.16 billion in 2023 and is projected to reach USD 21.84 billion by 2031, with a CAGR of 7.6% during the forecast period of 2024 to 2031.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Medication, Desmopressin, Emicizumab, Anti-fibrinolytics, Factor Replacement Therapy, Desmopressin and Fibrin Sealants, Monoclonal Antibodies, ITI Therapy, Gene Therapy, Fibrin Sealants, and Others), Route of Administration (Oral, Injectable, and Others), Diagnosis (Blood Test, Genetic Tests, and Others), Patient (Pediatric, and Adult), Type (Haemophilia A, Haemophilia B, Haemophilia C, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East and Africa
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), CSL (U.S.), BioMarin (U.S.), Spark Therapeutics, Inc. (U.S.), Chugai Pharmaceutical Co. Ltd. (Japan), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen (U.S.), Genentech Inc. (U.S.), Bayer AG (Germany), Ferring B.V. (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Haemophilia is a genetic disorder characterized by impaired blood clotting due to deficient or absent clotting factors in the blood. This condition leads to prolonged bleeding episodes, both internally and externally, which can be spontaneous or caused by injury. Management typically involves replacement therapy to restore clotting factor levels and prevent complications from bleeding episodes.
Haemophilia Market Dynamics
Drivers
- Growing Incidence of Haemophilia
Increasing incidence of haemophilia is attributed to several factors, including improved diagnosis capabilities, broader access to healthcare services, and heightened awareness among healthcare professionals and the general population. Additionally, genetic predisposition and demographic changes such as population growth and aging contribute to a larger patient pool requiring treatment. This trend fuels demand for clotting factor replacement therapies and encourages research into innovative treatments such as gene therapy. As the prevalence continues to grow globally, pharmaceutical companies and healthcare providers are motivated to develop and enhance therapies, thus driving market expansion and evolution.
- Increasing Disease Awareness
Enhanced awareness campaigns and educational initiatives contribute to earlier diagnosis and prompt initiation of treatment, which is critical for managing haemophilia effectively. As awareness grows, more patients are likely to seek medical care and adhere to treatment regimens, thereby expanding the market for clotting factor replacement therapies and emerging treatments such as gene therapy.
Opportunities
- Increasing Technological Advancements
Biotechnological breakthroughs have led to the development of more effective clotting factor replacement therapies, such as extended half-life products that reduce treatment frequency and improve convenience for patients. Moreover, advancements in gene therapy and gene editing technologies offer promising avenues towards potential cures by correcting the genetic defects underlying haemophilia. Improved diagnostic tools and monitoring devices enhance precision in treatment delivery and patient management, contributing to better outcomes and quality of life. These technological strides continue to shape the landscape of haemophilia treatment, fostering continuous innovation and addressing unmet medical needs in the market.
- Rising Government Initiatives
Government initiatives fosters a supportive regulatory environment, funding research and development, and improving access to treatment. Governments often collaborate with healthcare organizations and industry stakeholders to enhance awareness about haemophilia, promote early diagnosis through screening programs, and ensure affordability of therapies through healthcare reimbursement policies. By investing in infrastructure and healthcare systems, governments facilitate the availability of advanced treatments such as clotting factor replacements and gene therapies, thereby improving patient outcomes and quality of life.
Restraints/Challenges
- Stringent Regulatory Requirements
Regulatory agencies mandate rigorous clinical trials and extensive safety assessments for approval, which can delay the introduction of innovative treatments. These requirements not only increase development costs but also limit the number of therapies that successfully navigate the approval process. Additionally, differing regulatory standards across countries and regions create complexities in global market entry, further impeding timely access to new treatments for haemophilia patients worldwide.
- High Treatment Costs
The recurring expenses associated with clotting factor replacement therapies and emerging treatments such as gene therapy can impose a substantial financial burden, particularly in regions without adequate insurance coverage or healthcare subsidies. This cost barrier limits access to optimal care and innovative therapies, potentially compromising treatment outcomes and quality of life for patients. Moreover, the financial strain on healthcare budgets may delay investment in infrastructure and research, hindering advancements in haemophilia treatment options and overall market growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Haemophilia Market Scope
The market is segmented on the basis of type, treatment, route of administration, diagnosis, patient, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Type
- Haemophilia A
- Haemophilia B
- Haemophilia C
- Others
Treatment
- Medication
- Desmopressin
- Emicizumab
- Anti-fibrinolytics
- Therapy
- Factor Replacement Therapy
- Plasma-derived Factor Concentrates
- Factor VIII
- Factor IX
- Recombinant Factor Concentrates
- Factor VIII
- Factor VII
- Factor IX
- Plasma-derived Factor Concentrates
- Desmopressin and Fibrin Sealants
- Monoclonal Antibodies
- ITI Therapy
- Gene Therapy
- Fibrin Sealants
- Others
Route of Administration
- Oral
- Injectable
- Others
Diagnosis
- Blood Test
- Genetic Tests
- Others
Patient
- Pediatric
- 0 to 4
- 5 to 13
- 14 to18
- Adult
- 19 to 44
- 45+
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Haemophilia Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, patient, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.
North America dominates the market due to increasing demand for specialized treatments and higher healthcare spending, which will bolster market growth. Moreover, the region's high prevalence of bleeding disorders and increasing adoption of advanced technologies are additional factors contributing to the growth trajectory of the market in North America. These dynamics position the region as a key player in the global haemophilia treatment landscape.
Europe is expected to experience rapid growth, primarily driven by increasing incidences of haemophilia. The region's robust healthcare infrastructure and proactive government initiatives are pivotal in accelerating market expansion. These factors are expected to enhance accessibility to advanced treatments and therapies, thereby fostering significant advancements in haemophilia care across Europe.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Haemophilia Market Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Baxter (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Grifols, S.A. (Spain)
- CSL (U.S.)
- BioMarin (U.S.)
- Spark Therapeutics, Inc. (U.S.)
- Chugai Pharmaceutical Co. Ltd. (Japan)
- Octapharma AG (Switzerland)
- Novo Nordisk A/S (Denmark)
- Biogen (U.S.)
- Genentech Inc. (U.S.)
- Bayer AG (Germany)
- Ferring B.V. (Switzerland)
SKU-